Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy

In situ vaccination is a promising strategy to convert the immunosuppressive tumor microenvironment into an immunostimulatory one with limited systemic exposure and side effect. However, sustained clinical benefits require long-term and multidimensional immune activation including innate and adaptiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Junmeng, Ke, Yaohua, Liu, Qin, Yang, Ju, Liu, Fangcen, Xu, Ruihan, Zhou, Hang, Chen, Aoxing, Xiao, Jie, Meng, Fanyan, Yu, Lixia, Li, Rutian, Wei, Jia, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719518/
https://www.ncbi.nlm.nih.gov/pubmed/36463242
http://dx.doi.org/10.1038/s41467-022-35130-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719518/
https://www.ncbi.nlm.nih.gov/pubmed/36463242
http://dx.doi.org/10.1038/s41467-022-35130-7

Ejemplares similares